Breast Cancer Drugs Market - Forecast(2024 - 2030)

Breast Cancer Drugs Market Overview

The Breast Cancer Drugs Market is estimated to reach $32.7 billion by 2028, growing at a CAGR of 11.2% over the forecast period 2023-2028. The majority of cancer-related deaths among women worldwide are caused by breast cancer, which is the most frequent cancer in women. According to World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. By 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer. It is a heterogeneous malignancy that is divided into various subtypes in accordance with the status of the human epidermal growth factor receptor 2 (HER2, also known as ERBB2), the hormone receptors (HRs), the oestrogen receptor (ER) and the progesterone receptor (PR). The availability of pharmacological treatments depends on HR and HER2 status.

Breast Cancer Drugs Market Report Coverage

The report: “Breast Cancer Drugs Market – Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Breast Cancer Drugs Market.

By Type: Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors and Others.
By Therapy Type: Targeted Therapy, Immunotherapy, Hormonal Therapy, Chemotherapy and Others.
By Distribution Channel: Hospitals, Pharmacies, E-Commerce and Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia and the New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

• North America held the largest market share in 2022, owing to the rising prevalence of breast cancer in the region. Asia-Pacific is anticipated to grow the fastest during the forecast period of 2023–2028, owing to the initiatives taken by several organizations to generate funds for Breast Cancer treatment and research.
• The rising number of cases and prevalence of Breast Cancer are driving the global Breast Cancer Drug market.
• Breast Cancer Drugs, like hormone receptors and antimetabolite drugs, have the capacity to kill or control the cancerous cells and can prolong patient life by causing cancer to stop growing or shrinking.

Based on type, the Breast Cancer Drugs market is further segmented into Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors and Others. The HER2 Inhibitors segment held the largest revenue market share in 2022, owing to the rising prevalence of breast cancers that are HER2-positive. According to a breast cancer article from 2021, 20–25% of all breast tumors are HER2 positive (human epidermal growth factor receptor 2). However, CDK 4/6 Inhibitors segment is estimated to grow at the fastest CAGR of 12.2% over the forecast period 2023-2028 as it is anticipated that CDK 4/6 Inhibitors would increase the survival rate of individuals with metastatic breast cancer.

Breast Cancer Drugs Market Segment Analysis – by Therapy Type

Based on therapy type, the Breast Cancer Drugs market is further segmented into Targeted Therapy, Immunotherapy, Hormonal Therapy, Chemotherapy and Others. The Targeted Therapy segment held the largest revenue market share in 2022, as targeted therapies can be used alone or in conjunction with other therapies such as radiation therapy, surgery or conventional chemotherapy. Additionally, it aids in the elimination of cancer cells by the immune system. According to an article published by Samitivej Hospital, targeted therapy offers around an 80% success rate in most cases. However, the Hormonal Therapy segment is anticipated to grow at the fastest CAGR of 11.7% over the forecast period of 2023–2028, as hormonal receptors slow or stop the growth of tumors that rely on hormones for growth. The fact that some cancers use the body's natural hormones to fuel their growth is a major factor why hormonal receptors therapy is recommended.

Breast Cancer Drugs Market Segment Analysis – by Geography

Based on Geography, North America Breast Cancer Drugs Market accounted for 32% revenue share in 2022, owing to rising breast cancer awareness and the development of R&D infrastructure in the region. According to the American Cancer Society, there are around 287,850 new cases of invasive breast cancer in women in the United States in 2022. However, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period 2023-2028, owing to the increasing need for medicines globally. Many pharmaceutical companies have also established manufacturing and R&D facilities in the region.

Breast Cancer Drugs Market Drivers

Increasing Cases of Breast Cancer Globally Require Effective Breast Cancer Drugs to Treat the Disease:

According to the American Cancer Society, it is estimated that there would be 287,850 new incidences of invasive breast cancer, 51,400 cases of DCIS and 43,250 deaths from breast cancer in 2022. 83% of invasive breast cancers are diagnosed in women 50 years of age and older and 91% of breast cancer fatalities take place in this age group. Half of breast cancer deaths occur in women 70 years of age or older. Breast cancer is the most common cancer type. Breast cancer's rising prevalence and incidence are anticipated to drive the Breast Cancer Drugs market during the forecast period 2023-2028. 

Development of Advanced Technology and Cutting-edge Treatments:

The introduction of new drugs and advanced technology for the treatment of Breast Cancer is one of the crucial aspects that is anticipated to considerably fuel market growth. The market is expected to benefit from these innovative technological advances as they frequently result in improved patient treatment outcomes. Additionally, some of the newly released drugs are particularly intended for the treatment of breast cancer that was formerly incurable or for past therapies that did not improve patient results. The FDA authorized Enhertu (fam-trastuzumab deruxtecan-nxki) in August 2022 for the treatment of patients with metastatic HER2-low breast cancer. A limited trial of patients with HER2-low cancers later validated the laboratory findings that Enhertu could also inhibit the growth of HER2-low cancer. This led to a larger trial being conducted, which resulted in the new approval and significantly increased the number of patients who could be treated with the drug. It is anticipated that these factors have a favorable effect on the market throughout the forecast period of 2023–2028.

Breast Cancer Drugs Market Challenges

Unfavorable Drug Side Effects:

The serious complications and side effects of breast cancer treatments may restrain the expansion of the breast cancer drug market. The negative effects of targeted therapy include elevated blood pressure, digestive problems like diarrhea and facial blemishes. The severe side effects of targeted therapy can include ulcer development and rashes in various body parts. Similarly, side effects of immunotherapy include drowsiness and indigestion. According to an article published by the National Library of Medicine (NLM), the most often observed side effects were fatigue (74.7%) and nausea and vomiting (79.3%). Among the other notable side effects that are commonly observed are reduced appetite (65.5%), altered tastes (60.9%), hair loss (60.0%), dry mouth (51.7%) and diarrhea (51.7%). Over 50% of patients reported experiencing at least one of these adverse effects. These unfavorable side effects are anticipated to constrain market expansion during the forecast period of 2023–2028.

Key Market Players:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Breast Cancer Drugs Market. The top 10 companies in the Breast Cancer Drugs Market are:

1. AstraZeneca
2. Eli Lilly & Co
3. Pfizer Inc.
4. Novartis AG
5. Amgen Inc.
6. F. Hoffmann-La Roche AG
7. Merck & Co.
8. Abbvie
9. Natco Pharma
10. Bristol-Myers Squibb

Recent Developments

• In October 2022, Eli Lilly & Company announced a final agreement to acquire Akouos, a personalized genetic healthcare company that is creating a range of the first adeno-associated viral gene therapies for the treatment of inner ear diseases, including hearing impairment.
• In December 2021, Novartis revealed that it had entered into a binding agreement to acquire all of the outstanding shares of UK-based Gyroscope Therapeutics, a provider of ocular gene therapy. Geographic atrophy (GA), a more severe type of dry age-related macular degeneration (AMD), causes irreversible visual loss over time. 
• In September 2020, Natco Pharma announced that Lupin, its marketing partner, had introduced Lapatinib Tablets (250 mg) in the United States after Natco got the final approval for its Abbreviated New Drug Application (ANDA) from the United States Federal Drug Administration (USFDA).

Relevant Titles

Anti-Cancer Drugs Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0965

Oncology Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 1226

Cancer Biomarkers Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis
Report Code: HCR 0194

For more Lifesciences and Healthcare Market reports, please click here